HPP-971 is under clinical development by Anteris Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect HPP-971’s likelihood of approval (LoA) and phase transition for Inflammation took place on 05 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HPP-971 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
HPP-971 is under development for the treatment of inflammatory disorders associated with oxidative stress and non-alcoholic steatohepatitis (NASH) and renal diseases. It is administered through oral route. The drug candidate is a small molecule, which acts by targeting Bach1 and Nrf2. It is developed based on using TTP translational technology. It was also under development for the treatment of renal atrophy, hypertension, diabetes, autoimmune diseases and obesity.
Quick View HPP-971 LOA Data
|Highest Development Stage|